novi

About novi

novi (joinnovi.com) is a compounded GLP-1 telehealth platform founded in 2025, offering semaglutide and tirzepatide at $174 to $283 per month. Among the newest providers in our directory, novi shows early promise with a 4.4 Trustpilot rating, though across only 10+ reviews.

The early Trustpilot performance is the most notable data point — a 4.4 rating, even with limited volume, suggests initial patients are having positive experiences. This puts novi ahead of several similarly new competitors that have zero reviews or negative ratings. However, 10 reviews is far too few to draw reliable conclusions about consistent service quality.

Clinically, novi operates at the minimum level of service. Provider quality is rated low, with no lab testing, no dietitian access, and medium ongoing support. Trust and compliance transparency is rated low, and cost transparency is medium. Pharmacy partners are not publicly disclosed, and CoA testing status is unknown.

There is no BBB listing, no insurance acceptance, and the standard no-refund-on-shipped-medications policy applies. The pricing is competitive for the compounded market, falling in the mid-range for both semaglutide and tirzepatide.

novi is worth watching as it builds its review base, but the current data is insufficient to recommend it over established competitors. Patients who choose novi should ask about pharmacy sourcing, request a Certificate of Analysis, and understand the limitations of a platform this early in its lifecycle.

At a Glance